|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
Intensive Review of Nephrology - LIVE STREAMING
With over 70 interactive lectures, case discussions, board preparation sessions, and supplementary lectures, this CME program provides a comprehensive review of state-of-the-art nephrology practices offered by the clinical faculty of Harvard Medical School.
It offers accelerated learning for:
- Clinicians seeking a practical and comprehensive review that ensures they are up to date across all major areas of nephrology:
• The latest options for diagnosis: what to choose, when, and wh... |
|
|
Contemporary Issues in the Management of Patients With Primary Biliary Cholangitis: An Interprofessional Approach
An interprofessional faculty of gastroenterology clinicians discuss real-world issues in managing patients with primary biliary cholangitis. Two mini-lectures serve as the foundation for understanding the diagnostic evaluation and risk factors of primary biliary cholangitis. Three cases foster a robust discussion, among the 5 faculty, of clinical decision-making around the roles, benefits, and limitations of approved and investigational pharmacologic treatment options. The program format foste... |
|
|
LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity
Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho... |
|
|
Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment
There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the tre... |
|
|
Overcoming Challenges to Recognizing, Diagnosing, and Managing Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered rare, is more prevalent than previously thought. Diagnosing this condition can be a challenge, as early symptoms may be nonspecific and attributable to aging, whereas later more severe symptoms can be mistaken for other cardiovascular conditions such as heart failure or may be confused with other causes of amyloidosis. This can be particularly problematic, as it can delay appropriate treatment.
Advances in noninvasive methods f... |
|
|
Long-Chain Fatty Acid Oxidation Disorders: Advances in Nutritional Management
Target Audience
This activity is designed to meet the educational needs of Registered Dietitians.
Program Overview
Long-chain fatty acid oxidation disorders (LC-FAODs) are characterized by acute crises of energy production and chronic energy deficiency during times of physiologic stress and fasting. Clinical complications include recurrent episodes of rhabdomyolysis, weakness, hepatic dysfunction, severe hypoglycemia, hyperammonemia, and cardiomyopathy. Despite a traditional diet therapy,... |
|
|
Crisis Intervention in End-of-Life Care
Crisis Intervention in End-of-Life Care is a 3-hour online continuing education (CE) course that examines the dynamics of end-of-life care as they relate to the patient, family members, paid caregivers, and medical staff.
For families and patients at the end of life, crisis is often a constant companion. Every medical decision, communication issue, patient decline or dip, and family conflict or disagreement requires a thoughtful understanding of the patient’s wishes, family functioning, m... |
|